TERN-501 Market

“TERN-501 Market Size, Forecast, and Emerging Insight − 2032” report provides comprehensive insights about TERN-501 for Non-alcoholic Steatohepatitis (NASH) in Japan. A detailed picture of the TERN-501 for NASH in Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the TERN-501 for NASH. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TERN-501 market forecast analysis for NASH in Japan, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in NASH.

Drug Summary

TERN-501 is a THR-β agonist with high metabolic stability, enhanced liver distribution, and greater selectivity for THR-β compared to other THR-β agonists in development. TERN-501 has high liver distribution and is 23-fold more selective for THR-β than THR-α activation, thereby minimizing the risk of cardiotoxicity and other off-target effects associated with non-selective THR stimulation. Finally, TERN-501 has been designed to be metabolically stable and is therefore expected to have little pharmacokinetic variability and a low clinical dose, making it an attractive candidate for use in fixed-dose combinations for NASH treatment. 

In June 2021, Terns announced positive top-line data from the Phase IIa LIFT study of TERN-101 in NASH patients. Based on the recorded positive results, the company planned to initiate a Phase IIa clinical trial of TERN-101 co-administered with the thyroid hormone receptor beta agonist TERN-501 in the first half of 2022, with top-line data expected in the second half of 2023. Terns reported positive top-line single-ascending and multiple-ascending dose (SAD/MAD) data from Phase I proof of concept clinical trial in November 2021. The DUET Phase IIa clinical trial of TERN-501 alone and combined with TERN-101 is ongoing, with top-line data expected in the third quarter of 2023. 

The company expects to initiate a Phase IIb/III clinical program of TERN-501 ± FXR in 2024 for NASH.

Scope of the Report 

The report provides insights into:

• A comprehensive product overview including the TERN-501 description, mechanism of action, dosage and administration, research and development activities in Non-alcoholic Steatohepatitis (NASH).
• Elaborated details on TERN-501 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the TERN-501 research and development activities in NASH across Japan.
• The report also covers the patents information with expiry timeline around TERN-501.
• The report contains forecasted sales of TERN-501 for NASH till 2032.
• Comprehensive coverage of the late-stage emerging therapies for NASH.
• The report also features the SWOT analysis with analyst views for TERN-501 in NASH.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TERN-501 Analytical Perspective by DelveInsight

• In-depth TERN-501 Market Assessment

This report provides a detailed market assessment of TERN-501 for Non-alcoholic Steatohepatitis (NASH) in Japan. This segment of the report provides forecasted sales data from 2029 to 2032.

• TERN-501 Clinical Assessment

The report provides the clinical trials information of TERN-501 for Non-alcoholic Steatohepatitis (NASH) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights  

• In the coming years, the market scenario for Non-alcoholic Steatohepatitis (NASH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TERN-501 dominance.
• Other emerging products for NASH are expected to give tough market competition to TERN-501 and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TERN-501 in NASH.
• Our in-depth analysis of the forecasted sales data of TERN-501 from 2029 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TERN-501 in NASH. 

Key Questions

• What is the product type, route of administration and mechanism of action of TERN-501?
• What is the clinical trial status of the study related to TERN-501 in Non-alcoholic Steatohepatitis (NASH) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TERN-501 development?
• What are the key designations that have been granted to TERN-501 for NASH?
• What is the forecasted market scenario of TERN-501 for NASH?
• What are the forecasted sales of TERN-501 in Japan?  
• What are the other emerging products available and how are these giving competition to TERN-501 for NASH?
• Which are the late-stage emerging therapies under development for the treatment of NASH?